Biologic predictors of clinical improvement in rituximab-treated refractory myositis

BACKGROUND: To examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as predictors of disease improvement in refractory myositis patients treated with rituximab. METHODS: In the RIM Trial, all subjects received rituximab on 2 consecutive week...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, Ann M., Crowson, Cynthia S., Hein, Molly, de Padilla, Consuelo Lopez, Olazagasti, Jeannette M., Aggarwal, Rohit, Ascherman, Dana P., Levesque, Marc C., Oddis, Chester V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574570/
https://www.ncbi.nlm.nih.gov/pubmed/26382217
http://dx.doi.org/10.1186/s12891-015-0710-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574570/
https://www.ncbi.nlm.nih.gov/pubmed/26382217
http://dx.doi.org/10.1186/s12891-015-0710-3

Ejemplares similares